Potential of mucoadhesive chitosan glutamate microparticles as microbicide carriers – antiherpes activity and penetration behavior across the human vaginal epithelium

Emilia Szymańska¹, Małgorzata Krzyżowska²,³, Krzysztof Cal³, Barbara Mikolaszek⁴, Jakub Tomaszewski⁵, Sławomir Wołczyński⁶ and Katarzyna Winnicka⁷

¹Department of Pharmaceutical Technology, Medical University of Białystok, Białystok, Poland; ²Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden; ³Military Institute of Hygiene and Epidemiology, Warsaw, Poland; ⁴Department of Pharmaceutical Technology, Medical University of Gdańsk, Gdańsk, Poland; ⁵Private Obstetric and Gynecological Clinic, Tomaszewski Medical Centre, Białystok, Poland; ⁶Department of Reproduction and Gynecological Endocrinology, Medical University of Białystok, Białystok, Poland

ABSTRACT
Chitosan glutamate (gCS) spray-dried microparticles appear promising carriers to overcome challenges associated with vaginal microbicide delivery. This study aimed at elucidating the penetration and mucoadhesive behavior of developed gCS multuni1t carriers with zidovudine (ZVD) as a model anti-retroviral agent in contact with excised human vaginal epithelium followed with an examination of in vitro antiherpes activity in immortal human keratinocytes HaCaT and human vaginal epithelial cells VK2-E6/E7. Both ZVD dispersion and placebo microparticles served as controls. Microparticles displayed feasible (comparable to commercial vaginal product) mucoadhesive and mucoretention characteristics to isolated human vaginal tissue. Ex vivo penetration studies revealed that gCS increased the accumulation of active agent in the vaginal epithelium but surprisingly did not facilitate its penetration across human tissue. Finally, the obtained antiviral results demonstrated the potential of gCS as an antiherpes adjunctive, whose mode of action was related to blocking viral attachment.

ARTICLE HISTORY
Received 26 July 2021
Revised 28 September 2021
Accepted 4 October 2021

KEYWORDS
Chitosan glutamate; microbicide vaginal carrier; microparticles; mucoretention; ex vivo penetration studies; human vaginal epithelium; HSV-2; antiviral activity

CONTACT Emilia Szymańska emilia.szymanska@umb.edu.pl  Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, Białystok 15-222, Poland

1. Introduction
Sexually transmitted diseases (STDs), including bacterial, viral, and parasites infections are relevant and still existing public health issues worldwide (Shannon & Klausner, 2018; Seña et al., 2020; World Health Organization, 2021). In recent years, the prevalence of genital herpes caused by herpes simplex virus type 1 or 2 (HSV-1/2) has gradually increased, and resistance to conventional antiviral drugs (e.g. acyclovir) has been reported (McQuillan et al., 2018). HSV increases the risk of HIV acquisition by forming breaches in the genital epithelium and creating a state of chronic inflammation. It should be noted that HSV is able to reactivate periodically, allowing the transmission to occur, even in the absence of clinical symptoms (Sauerbrei, 2016). At present, the conventional treatment (by oral acyclovir and its analogues) does not cure but basically help to reduce the duration and severity of recurrent genital herpes. Therefore, there is a need to develop novel strategies aiming at preventing either new infection or frequent recurrence of HSV episodes.

Among goals and priority actions established by the WHO Global Health Sector Strategy on Sexually Transmitted Infections (2016–2021), vaginal microbicides present a promising prophylactic approach against STDs, including genital herpes (World Health Organization, 2021). Microbicides refer to topically (vaginal or rectal) applied antimicrobial or antiviral agents intended to prevent infections (Karim & Karim, 2007). Several classes of microbicides have been proposed as HSV prophylactic strategy (AVAC, 2021; Clinical Trials, 2021; Cordis, 2021), but effective and safe products are still not available. Although efforts have been made toward finding and testing proper active microbicide agents, currently, more focus has been made on the development of novel delivery systems which ideally would provide the patient with a convenient vaginal application and simultaneously preserve or even enhance the protecting microbicide effect (Mesquita et al., 2019).

Chitosan is a natural copolymer derived from chitin which consists of glucosamine and N-acetylglucosamine units. With regard to its cationic nature, chitosan binds to mucosal surfaces and thus has been extensively studied for a number of biomedical and pharmaceutical applications (Ahmed & Aljaeid, 2016; Ahsan et al., 2018; Potáš et al., 2020). We have previously shown that chitosan could be successfully used in the technology of carriers for vaginal candidiasis treatment (Szymańska et al., 2014). This capability of increasing the
pharmacological action of an antimicrobial agent provides the opportunity for combination therapy in which chitosan acts as the effective excipient and simultaneously takes an active part in the treatment process. Apart from antifungal activity, chitosan has gained attention as an antiviral adjunctive directly impacting virus infectivity (Russo et al., 2014; Loutfy et al., 2020; He et al., 2021; Safarzadeh et al., 2021). In our previous studies, we observed that upon contact with vaginal fluid, chitosan creates a swellable hydrogel matrix which may serve as a barrier and additionally support mucosal tissue from the risk of infection (Szymanska et al., 2019).

Vaginal administration (including microbicides) is considered beneficial as it allows administration of lower drug dose, maintains its steady state levels and is not affected by gastrointestinal disturbances when compared to the oral route (Swarbrick, 2007). However, effective treatment with conventional vaginal preparations (creams, gels) containing antimicrobial drugs is often inconvenient for patients, which results in low product acceptability. What is more, until now, there are no vaginal microbicide formulations available on the pharmaceutical market.

We have recently demonstrated a feasible potential of spray-dried microparticles composed of water-soluble chitosan derivative – chitosan glutamate (gCS) as a microbicidal delivery system for vaginal application (Szymanska et al., 2019). By applying an experimental design approach, the technology of spray-drying gCS microparticles was optimized, and the obtained multiunit carriers were characterized by favorable physical and biopharmaceutical properties.

This study aims at investigating the biological potential of developed gCS multiunit carriers loaded with zidovudine (ZVD) – model antiretroviral agent belonging to a class of reverse transcriptase inhibitors. Apart from mucoadhesive potential, the precise goal was to examine the effect of gCS microparticles against HSV-2 in two relevant cell lines: immortal human keratinocytes HaCaT and human vaginal epithelial cells VK2-E6/E7. Taking into consideration that chitosan particles are considered to improve the bioavailability of active agents by enhancing their transport through the epithelial cells (Caramella et al., 2010), particular effort was made toward evaluation ex vivo penetration and retention behavior of a model microbicidal agent encapsulated in gCS multiunit formulations across the human vaginal epithelium.

2. Materials and methods

2.1. Materials

Highly purified medical grade gCS was purchased from Heppe Medical Chitosan (Haale, Germany). Molecular weight (Mn 101 kDa) and average molecular weight (Mw 247 kDa) were determined with PVP-calibration on Agilent 1260 Infinity GPC/SEC at 35 °C with a refractive index detector (Agilent Technologies, Santa Clara, CA). The deacetylation degree (80.2%) was determined by titration method according to Czechowska-Biskup et al. (2012), whereas the viscosity of 1% (w/w) aqueous solution (30 mPas) was measured with rotational viscometer Viscotester 6 Plus ThermoHaake (Karlsruhe, Germany) at ambient temperature. The protein and sulfated ashes content was below 0.5% and 1%, respectively (according to the manufacturer).

Zidovudine in crystalline form (batch no. ZD1900515) was obtained from Hetero Labs Limited (Hyderabad, India). Methanol (HPLC grade) was obtained from Merck (Darmstadt, Germany), sodium azide was from Sigma-Aldrich (Darmstadt, Germany), whereas hydroxyethylcellulose (HEC) (with viscosity of 1% (w/w) aqueous solution of approximately 40 mPas at 25 °C) was purchased from Fluka (Buchs, Switzerland). Water for HPLC was distilled and passed through a reverse osmosis system Milli-Q Reagent Water System (Billerica, MA). Simulant vaginal fluid (SVF) pH 4.2 for mucoadhesive and penetration tests was obtained according to Owen & Katz (1999) with the following composition (g): sodium chloride, 3.51; lactic acid, 2.00; potassium hydroxide, 1.40; calcium hydroxide, 0.22; acetic acid, 1.00; urea, 0.4; glycerol, 0.16; and glucose, 5.0 and water up to 1000 mL. Other chemicals were purchased from Chempur (Piekary Śląskie, Poland).

Dulbecco’s modified Eagle medium (DMEM), defined keratinocyte serum-free medium (Ker-SFM), minimum essential medium with alpha modification (α-MEM), fetal calf serum (FCS), phosphate buffer saline (PBS), human recombinant epidermal growth factor (EGF), bovine pituitary extract, penicillin, and streptomycin were purchased from Thermo Fisher Scientific (Poznań, Poland). HSV-2 strain 333 isolated from the University of Gothenburg (Gothenburg, Sweden) was propagated in Vero cells. Immortal human keratinocytes cell line HaCaT was from Cell Line Service CLS GmbH (Eppelheim, Germany), whereas human vaginal epithelial cells VK2-E6/E7 (CRL 2616) were purchased from American Type Culture Collection (Manassas, VA). A plasmid vector pCR 2.1 containing envelope glycoprotein (gB) gene fragment was constructed and purified by the Institute of Biochemistry and Biophysics Polish Academy of Sciences (Warsaw, Poland).

2.2. Human vaginal epithelium

Local Bioethics Committee (Medical University of Białystok) revised and approved the study protocol using human tissue under the no. R-I-002/462/2018. Freshly excised human vaginal epithelium was obtained from the Private Clinic of Obstetrics and Gynecology (Białystok, Poland) from premenopausal women undergoing gynecological plastic surgery. Apart from age, no information concerning the patient’s identity was disclosed. Directly after the surgery, tissue specimens were preserved in the isotonic saline solution and kept at –20 °C for no longer than 60 days. In prior experiments, tissue was thawed at room temperature, cut into pieces (weight 300–350 mg) and microscopically checked for tissue integrity.

2.3. Microparticles preparation

Placebo (P) and two drug-loaded formulations MB1 and MB2 differed in gCS:ZVD ratio 2:1 and 5:1 (w/w), respectively, were obtained by using a Büchi Mini Spray Dryer B-290 (Flawil, Switzerland) according to the method previously
described by our group (Szymanska et al., 2019). Briefly, 3% (w/w) gCS aqueous dispersion was mixed with a water–ethanol drug solution under continuous stirring. Based on previously established studies, spray drying was performed at 120°C in an opened loop configuration at a spray rate of 1.8 mL/min with aspirator blower capacity (95%) and pressure (40 mm Hg). The production yield was 75%.

2.4. Microparticles characterization

Microparticles were characterized in terms of moisture, ZVD content, and encapsulation efficiency evaluated using HPLC method after previously described extraction procedure (Szymanska et al., 2019) and volume particles size distribution (examined using light diffraction analyzer Mastersizer 3000 equipped with HydroEV probe; Malvern Instruments, Malvern, UK). The morphology of microparticles was examined by a scanning electron microscope (SEM, Phenom Pro Generation 5, Thermo Fisher, Eindhoven, Netherlands) by in-line detection mode at 5 kV or 10 kV with a BSD detector. Before the microscopic observations, approximately 0.5 mg of powder was spitted on conductive carbon adhesive tabs and coated with a thin layer of gold in an ion sputtering device (4.9 nm). The obtained micrographs were evaluated for particle size and shape and tendency to create agglomerates. The surface of the microparticles was assessed, with a focus on the presence of cracks in the shells or ZVD crystals.

Viscosity measurements were conducted at ambient conditions with rotational viscometer Viscotester 6 Plus ThermoHaake (Thermo Scientific, Braunschweig, Germany) equipped with a rotor TL 6 (for formulation MC1) and TL 7 (for formulation MC2 and P). Before tests, each microparticles sample (whose amount corresponded to drug dose 10 mg/mL) was placed in a vial containing SVF pH 4.2 and shook thoroughly until complete dispersion of the sample. Tests were carried out with a rotational speed of 20/min 10 min after placing the preparation’s sample (10 mL) into the measuring tube. The values of dynamic viscosities were noted after 30 s. The results were shown as the average of three independent tests.

2.5. Mucoadhesive measurements

The ex vivo mucoadhesive behavior of microparticles in contact with human vaginal epithelium was assessed with texture analyzer TA.XT. Plus (Stable Microsystems, Godalming, UK) equipped with a A/MUC measuring system at 37 ± 2°C as previously described (Szymańska et al., 2018). A sample of placebo or MB microparticles (100 mg) was adhered to the platform A/MUC with bioadhesive tape and wetted with 100 μL of SVF (pH 4.2), whereas the tissue sample (surface area 0.8 cm²) was fixed with cyanoacrylate glue to the upper tester probe. Afterwards, the probe was lowered onto the surface of microparticles with a constant speed of 0.5 mm/s. After keeping a contact time for 100 s under an initial contact force of 0.5 N, the planes were separated at a constant rate of 0.1 mm/s. The maximum detachment force was recorded directly from Texture Exponent 32 software, and the work of mucoadhesion was measured from the area under the force vs. distance curve. Cellulose paper was applied as a negative control. In contrast, a commercially available mucoadhesive vaginal product with lubricating properties Replens MD™ composed of polycarbophil, carbomer homopolymer type B, hydrogenated palm oil glyceride, glycerin, mineral oil, sorbic acid, sodium hydroxide, and purified water (Lil Drug Store Products, Cedar Rapids, IA, US) was used as a positive control. Each experiment was performed five times.

2.6. Mucoretention behavior upon dilution with simulant vaginal fluid

To examine mucoretention behavior of microparticles formulations upon dilution with SVF (pH 4.2), the measurements were carried out using human vaginal epithelium attached to a self-constructed thermostated inclined steel plate at 36 ± 2°C. The kinetic detachment was determined from the delay in the sample slipping and the overall detachment from the mucosal tissue (Balasch-Risueño & López, 2019). Before analysis, MB1 and MB2 or placebo formulation in the amount corresponding to MB2 was placed in a vial containing SVF (pH 4.2) and shook thoroughly until complete sample dispersion. The average SVF volume of 3 mL was chosen for studies according to data that daily production of vaginal fluid is 2–6 mL per day (Godley, 1985; Bernkop-Schnürch & Hornof, 2003) and the final ZVD concentration in microparticles’ dispersion was 10 mg/mL. Water and commercially available mucoadhesive vaginal product (diluted in a comparable manner as microparticles MB2) were used as a negative and positive control. A diluted sample (1 mL) was gently spread on the human vaginal tissue (area 1 cm²) and fixed with cyanoacrylate glue to a horizontally positioned plate and left for 5 min. To start the run, the plane was set at a 45° inclination which simulated changing body positions. The amount of sample detached from the tissue was weighted (Radwag XA 60/220, Radom, Poland) after 30 s, 1 min, 3, 5, 10, and 30 min. Each value was compared with the initial weight of the applied sample to build a mucoretention vs. time plot. The average of three independent registered weights at each time interval was measured. The mucoretention expressed as a percentage of the sample adhered to mucosal tissue was calculated through the following formula:

\[ \text{Mucoretention} = \frac{(P_0-P_t)}{P_0} \times 100 \]

where \( P_0 \) is the initial sample weight applied on the tissue plane and \( P_t \) is the weight of the sample detached from the tissue plane at each time interval.

2.7. Penetration studies

Penetration studies were conducted in a flow-through cell system equipped with thermostated Teflon Bronaugh diffusion chambers in accordance with draft guideline on quality and equivalence of topical products published by the
European Medicine Agency (European Medicines Agency, 2021). In brief, the human vaginal epithelium was sandwiched between the two compartments with the epithelial side facing the donor compartment and equilibrated with isotonic saline solution (pH 6.6) for 60 min. The diffusion area of the tissue was 0.81 cm². To exclude the impact of drug release behavior on penetration characteristics, microparticles were dispersed in SVF prior to penetration testing. For this purpose, the proper amount of MP formulation (which amount corresponded to 5 mg ZVD dose) or pure ZVD was suspended in 0.5 g of SVF or SVF with the addition of 3% (w/w) HEC as a universal placebo gelling agent, respectively. The donor compartments of all chambers were protected with parafilm. The acceptor medium (isotonic saline solution with the addition of 0.005% sodium azide, pH 6.6) was then recirculated beneath the vaginal tissue at a constant rate of 30 mL/h. At predetermined time intervals (1, 2, 4, 6, 8, and 24 h), samples of acceptor fluid were withdrawn, filtered through cellulose acetate filters 0.2 μm and analyzed directly for drug content using HPLC method. The samples were replaced with the same volume of acceptor solution to assure sink conditions. Permeation profile was formed by plotting the cumulative amount of ZVD permeated through cellulose acetate filters 0.2 μm and analyzed directly for drug content using HPLC method. The samples were replaced with the same volume of acceptor solution to assure sink conditions. Permeation profile was formed by plotting the cumulative amount of ZVD permeated through the human vaginal epithelium per unit surface area (μg/cm²) vs. time. Permeability flux expressed as changes in concentration of active agent permeated to acceptor medium per unit area per unit time was calculated as follow:

\[
\text{Flux} = \frac{\Delta c}{\Delta t} \times \frac{V}{A}
\]

where \(\Delta c/\Delta t\) represents changes in concentration of the active agent in the acceptor compartment per unit time (μg/mL/h), \(V\) is the volume of acceptor compartment (mL), and \(A\) represents exposed surface area (cm²).

### 2.8. Assessments of drug retention and drug recovery

At the end of the studies, drug dispersion from the donor compartment was carefully aspirated to a flat-bottomed flask, washed with SVF (pH 4.2) until complete removal of drug from the top of the tissue and incubated in a water bath (1 h, 150 rpm, 30°C). After centrifugation (4000 rpm, 15 min), the aspirate was filtered through cellulose acetate membrane filters 0.2 μm, diluted with mobile phase, and analyzed for drug content. The tissue was cut into pieces, immersed in methanol (10 mL), homogenized and incubated for 5 h in a water bath (30°C, 150 rpm). After having filtered through nylon membrane filters 0.2 μm, the extract was analyzed for the amount of drug retained in the human vaginal epithelium using the HPLC method.

### 2.9. Solubility measurements

The equilibrium solubility of ZVD was measured at 37 ± 0.5°C in SVF (pH 4.2) and isotonic saline solution. For this purpose, an excess of drug powder was added to the respective media and incubated in a water bath 24 h to reach equilibrium (37°C and 150 rpm). Afterwards, samples were centrifuged (4000 rpm for 15 min) to remove the undissolved drug, filtered through a cellulose membrane filter (0.2 μm) and determined by HPLC system. All measurements were done in triplicate, and the average drug solubility was reported in milligrams per milliliter along with standard deviation.

### 2.10. Analytical method

Drug concentrations in acceptor fluid, extracts and aspirate from donor compartments were determined by reverse-phase high-pressure liquid chromatography (HPLC Agilent Technologies 1200, Waldbronn, Germany) according to the method (Dunge et al., 2005) with modifications. The separation was achieved by isocratic elution using Zorbax Eclipse C18-BDS column (150 x 4.6 μm, 5 μm) at 30°C with a flow rate of 1 mL/min. The mobile phase composed of methanol and acetate buffer, pH 4.5 23:77 (v/v). HPLC validation method is summarized in Table 1. The presence of gCS, SVF (pH 4.2) or acceptor medium did not interfere with drug detection.

### 2.11. Cell lines and viruses

HSV-2 strain 333 isolate was propagated and titrated in Vero cells, which were maintained in a complete culture medium consisting of α-MEM with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin as previously described (European Medicines Agency, 2021). In contrast, human HaCaT keratinocytes were propagated in DMEM supplemented with 10% FCS, 10 U/mL penicillin, and 100 μg/mL streptomycin (Orlowski et al., 2014). The human epithelial vaginal VK2-E6/E7 cell line was maintained in Ker-SFM with the addition of 0.1 ng/mL human recombinant EGF, 0.05 mg/mL bovine pituitary extract, and additional calcium chloride 44.1 mg/L (at a final concentration of 0.4 mM).

### 2.12. HSV infection in vitro

In vitro activity of MB2 and corresponding placebo formulation toward HSV-2 infection in cultured HaCaT and VK2-E6/E7 cells was determined by attachment assay (Bagdonaite et al., 2015). For attachment tests, formulations diluted to 0.5 mg/mL in complete culture medium, mixed with HSV-2 (with a multiplicity of infection (MOI) 0.1) were added to 24-well plates containing pre-chilled (at 4 ± 0.5°C for 1 h) HaCaT or VK2-E6/E7 cell monolayers (1 x 10⁵ cells per well). To allow viral attachment, plates were incubated for 1 h at 40 ± 0.5°C. After removing the unattached formulations and unabsorbed HSV, cells were rinsed with PBS and overlaid with fresh culture medium, followed by further incubation at 37.0 ± 1°C.

#### Table 1. RP-HPLC validation method summary.

| Parameters | Value |
|------------|-------|
| Linearity (μg/mL) | 0.5–20 μg/mL |
| Regression equation | 60.856x + 0.6792 |
| Regression coefficient (R²) | 0.9955 |
| Intra-day precision (% RSD) | 1.89 |
| Inter-day precision (% RSD) | 1.94 |
| Limit of detection LOD (μg/mL) | 0.11 |
| Limit of quantification LOQ (μg/mL) | 0.34 |

---
For penetration assays, HaCaT and VK2-E6/E7 cells were infected with HSV-2 (with a MOI 0.1) for 1 h at 4.0 ± 0.5 °C. Next, the unbound virus was washed away with cold PBS, and the cells were incubated with formulations diluted to 0.5 mg/mL in a complete culture medium for 1 h at 37 ± 1 °C. After this time, cells were rewashed and incubated for further 20 h at 37.0 ± 1 °C. Acyclovir with a concentration 100 mg/mL was used as a control. Studies were performed at least in triplicate.

### 2.13. HSV-2 titration

At 24 h post infection, total DNA was isolated from cell cultures using a DNA isolation kit (Eurx, Gdańsk, Poland). HSV-2 was detected using an HSV-2 probe labeled with carboxy-fluorescein FAM in a real-time PCR instrument Stratagene MX4000 Real-Time qPCR System (Agilent Technologies, Santa Clara, CA) as described by Namvar et al. (2005). A plasmid vector pCR 2.1 containing envelope glycoprotein (gB) gene fragment was constructed and purified by the Institute of Biochemistry and Biophysics Polish Academy of Sciences (Warsaw, Poland). Standard curve analysis was based on Ct values and serial of 10-fold dilutions of the plasmid standard with an initial concentration of $2.62 \times 10^{6}$ HSV-2 genome copy numbers per reaction. A standard curve was included in each PCR run. The amplification efficiency ($E$) was calculated from the standard curves, using the formula $E = 10\left(\frac{-1}{a}\right) - 1$, where $a$ is the slope. Data are expressed as the HSV-2 copy number per ng of the total DNA in the culture.

### 2.14. Statistical analysis

Quantitative variables were expressed as the mean ± standard deviation. A statistical analysis was performed with the Statistica 12.0 software. The normality of results was checked using the Shapiro–Wilk test. The difference among the mean values of mucoadhesiveness, amount of drug permeated through vaginal tissue and antiviral efficacy were tested using the Kruskal–Wallis test with post hoc nonparametric Dunn’s test for multiple comparisons. Differences between groups were considered to be significant at $p < .05$.

### 3. Results and discussion

#### 3.1. Microparticles characteristics

In present studies, the mucoadhesive and penetration behavior followed with in vitro efficacy toward HSV-2 of water-soluble chitosan derivative – gCS vesicular multifluoride carriers with a model microbicidal agent was investigated. Based on our previous studies, two formulations (MB1, MB2) obtained by the spray-drying technique varying in the mass ratio of polymer to the active substance (2:1 and 5:1, respectively) were selected for detailed analysis. Obtained formulations were characterized by a regular spherical shape, low moisture content, and high yield of ZVD encapsulation (Table 2) which point toward the good capacity of gCS to encapsulate the drug in the spray-drying process followed with the correct choice of process parameters.

Generally, microparticles did not differ in size, having a diameter below 30 µm (Table 2). The SEM analysis revealed the presence of substantial number of elongated drug crystals located superficially on the surface of MB1 and MB2 formulations (indicated by arrows on Figure 1). Both samples exhibited a tendency to create agglomerates, and a presence of smaller particles on the surface of larger ones was noted as a result of electrostatic interparticle forces. In Figure 1(A), some damaged hollow structures and cracks in the shells of polymer fragments can be distinguished. They indicate the higher amount of ZVD and polymer to drug ratio 2:1 led to the formation of more fragile particles during the spray-drying process, where a larger fraction of particles (above 20 µm) were susceptible to cracking.

#### 3.2. Mucoadhesive behavior

Ex vivo tensometric measurements elaborated the strength required to separate tested material from the isolated human vaginal epithelium. Figure 2 shows the maximum detachment force (imitating the mechanical stress resulting from the rapid body movements disturbing the contact between formulation and mucosal tissue) and work of mucoadhesion (mimicking the overall capability to retain in the application site upon continuous changing body positions) of tested formulations MB1–MB2, placebo and controls.

All tested microparticles were capable of adhering to human mucosal tissue displaying mucoadhesive potential as compared to applied controls – cellulose paper and

### Table 2. Characteristics of spray-dried drug-free (P) and ZVD-loaded microparticles (MB1–MB2) differed in chitosan glutamate to zidovudine mass ratio.

| Formulation | Encapsulation efficiency (%) | Moisture Content (%) | Particle size distribution (µm) | Viscosity (mPas at 25°C) |
|-------------|-----------------------------|----------------------|---------------------------------|--------------------------|
|             |                             | D_{10} | D_{50} | D_{90} |                        |
| MB1         | 87.2 ± 0.8                  | 5.2± 0.1 | 2.0   | 10.3  | 26.7                     | 170          |
| MB2         | 79.0 ± 1.2                  | 5.0± 0.2 | 2.2   | 12.2  | 28.2                     | 2420         |
| P           | –                           | n.d.  |       |       |                          | 2850         |

*Percentage of the amount of active agent encapsulated in microparticles assessed by HPLC method (Agilent Technologies 1200) vs. theoretical drug content × 100.

*^D_{10}, D_{50}, D_{90} value describes cumulative percentage particle undersize values for 10%, 50%, and 90% of MB by volume; assessed by Mastersizer 3000 (Malvern Instruments, Malvern, UK); n.d. – not determined.

*Measured with a rotational viscometer Viscotester 6 Plus ThermoHaake (Thermo Scientific, Braunschweig, Germany) upon microparticles dilution in SVF (pH 4.2) in the amount corresponded to drug dose 10 mg per mL.
commercially available vaginal mucoadhesive product. After initial wetting with SVF (pH 4.2), the viscous film appeared on the microparticles’ surface, which favored further interpenetration of gCS and mucin chains. A certain influence of polymer to ZVD ratio on mucoadhesive behavior was noted. Formulation MB1 (with gCS:ZVD mass ratio 2:1) was found less adhesive, which points that presence of drug impairs interaction between mucoadhesive polymer and vaginal epithelium. Similar observations were made by Meng et al. (2011) in respect of vaginal microcarriers with tenofovir and in Dott et al. (2013) work on electrospun HPMC nanofibers with diphenhydramine where the addition of drug resulted in a reduction in formulations mucoadhesiveness. Among tested microparticles, placebo formulation displayed the greatest values of the force of mucoadhesion, though microparticles MB2 exhibited slightly higher values of work of mucoadhesion parameter. All formulations presented a similar manner of examined mucoadhesive properties (Figure 2(A,B)) except for commercial vaginal product, which exhibited the greatest value of maximum detachment force but the profoundly lower value of work of mucoadhesion as compared to results obtained for MB formulations. This observation may be rather attributed to the semi-solid state of the commercial mucoadhesive product and may suggest its higher susceptibility to body movements.

Microparticles were additionally applied to mucoretention assay to investigate their mucoadhesive characteristic upon dilution with SVF, pH 4.2 (Figure 3).

The assumption of this test was to display whether diluted microparticles’ sample possesses greater ability to retain on the surface of the tissue than the one displayed by water, which interacts only through hygroscopic absorption. Microparticles in contact with SVF formed semi-solid shear-thinning fluids which differed in viscosity values (Table 2). Basically, all formulations flew down gradually from the vaginal tissue segment and the fastest sample slipping was observed within the first minutes of the test. It is worth noting that chitosan microparticles were capable of retaining on the human vaginal epithelium in a similar manner observed for a diluted sample of a commercial vaginal product. The overall detachment from the tissue was approximately 50% of the initial microparticles’ dose in comparison to more than 70% weight loss obtained for water within the first 5 min. MB2 and placebo formulations with greater viscosities were found more resistant to removal from inclined vaginal tissue displaying about 45% retention after 30 min. In turn, MB1 showed less than 35% retention on the tissue surface at the end of the test. Overall, microparticles, even upon dilution with SVF, can stay in contact with the mucosal tissue and assure
moderate drug retention on the vaginal epithelium upon mimicking body movements.

### 3.3. Penetration studies

In vitro/ex vivo penetration studies are important in evaluating the quality of developed topical formulations in preclinical tests and are considered an essential tool for predicting in vivo topical absorption (Frum et al., 2007; Godin & Touitou, 2007; Zhang et al., 2013). Among several approaches (including animal tissues or three-dimensional highly differentiated tissue models, e.g. EpiVaginal®) used to evaluate penetration potential, human explants are considered particularly useful in the preclinical stage of microbicide development but, due to limited availability, rarely applied in preclinical studies (Merbah et al., 2011; Patel & Rohan, 2017).

Although chitosan and its derivatives are widely explored as mucoadhesive polymers in the technology of drug carriers for vaginal delivery (Andersen et al., 2015), a limited number of studies have been devoted to the elucidation of the impact of chitosan-based carriers on drug penetration through vaginal tissue (Sandri et al., 2004; Frank et al., 2017). Based on the available literature, chitosan is rather regarded as a penetration enhancer promoting drug absorption either by opening tight junctions or by interacting with extracellular matrix components (Sonaje et al., 2012).

![Figure 2](image-url) **Figure 2.** (A) Maximum force of detachment ($F_{\text{max}}$) expressed in millinewtons (mN) and (B) work of mucoadhesion ($W_{\text{ad}}$) expressed in microjoules ($\mu$J) of microparticles MB1–MB2 and placebo formulation. Values are expressed as mean ± S.D., $n$ = 5; *significant differences with $p \leq 0.05$, ** with $p \leq 0.01$ and *** with $p \leq 0.001$ in comparison to control-1 (cellulose paper); ††significant differences with $p \leq 0.05$ and $p \leq 0.01$ in comparison to control-2 – commercially available mucoadhesive vaginal product, respectively.

![Figure 3](image-url) **Figure 3.** Mucoretention of microparticles MB1–MB2, placebo formulation (P) and controls: (1) water and (2) commercial mucoadhesive vaginal product. Values are expressed as mean ± S.D., $n$ = 3.

![Figure 4](image-url) **Figure 4.** Ex vivo permeation (expressed as the amount of agent measured in acceptor medium per tissue area unit) of zidovudine from microparticles MB1, MB2 and control – pure zidovudine in HEC/SVF (pH 4.2 through the human vaginal epithelium). Values are expressed as mean ± S.D. ($n$ = 4).
Therefore, in the present studies, we evaluated the penetration behavior of model antiretroviral agent ZVD from gCS microparticles across an excised human vaginal epithelium. Control studies with pure drug suspended in SVF (pH 4.2) with the addition of 3% HEC as a universal gelling agent with no impact on the epithelial transport (Tien et al., 2005) were additionally carried out. The applied model examines the passive diffusion of the active agent across the epithelium solely. To obtain a maximal penetration rate, a drug encapsulated in microparticles was applied on the tissue surface in infinite doses. According to the pKa value (9.68), ZVD was primarily present in a unionized state at SVF (pH 4.2). To fully estimate the influence of a drug carrier on the ZVD ability to permeate across cell membranes, the experimental setup for both control (HEC/SVF formulation) and gCS microparticles assured the maintenance of ZVD in the unionized form.

Figures 4 and 5 display the cumulative amount of ZVD permeated over time across the human vaginal epithelium and the permeation flux of the active agent, correspondingly.

In all tests, relatively high ZVD levels were found in the acceptor fluid at an early experimental stage. After 1 h incubation, the permeated fractions of ZVD from microparticles MB1 and MB2 were 18.5 and 23.5 μg/cm². In contrast, in control studies, the amount of active agent in the acceptor medium was above 25 μg per unit tissue’s area. Some differences in penetration behavior were observed between tested formulations and control. Basically, the amount of permeated drug was higher in control studies with ZVD dispersion in HEC/SVF where over 150 μg/cm² of ZVD was present in acceptor medium after 24 h. In contrary, in studies with gCS microparticles, the total amount of ZVD penetrated across excised vaginal tissue after 24 h incubation did not exceed 115 and 135 μg/cm² for MB1 and MB2, respectively (Table 3), suggesting the presence of gCS rather weakened than increased ZVD penetration across the epithelium.

This behavior is rather surprising, as chitosan has been considered so far as a penetration enhancer that facilitates drug absorption through mucosal membranes (Sandri et al., 2004; Caramella et al., 2010). For instance, Frank et al. (2014) demonstrated that chitosan nanocapsules were able to increase the Nile red penetration through vaginal tissue (Frank et al., 2014), whereas studies on formulation based on chitosan gel revealed that the presence of chitosan led to a higher permeation degree of imiquimod into vaginal tissue (Frank et al., 2017). It is worth noting that lower flux values of ZVD from microparticles were observed in the first hours of studies as compared to control examination with ZVD dispersion in HEC/SVF (Figure 5). This appeared desirable since antiretroviral reverse transcriptase inhibitors (such as ZVD) are related to a number of systemic adverse reactions (Sweetman, 2011). The presence of a higher amount of gCS in MB2 (with gCS:ZVD mass ratio 5:1) was responsible for a slight increase in the drug flux at 8 h of analysis, which may be beneficial when it comes to assuring prolonged microbicide activity.

The amount of drug recovered from the donor compartment after 24 h incubation (Table 3) fulfilled the criteria of acceptation (according to EMA, the acceptable limit of overall recovery is 90–100%) and confirmed the accuracy of the applied research method. Figure 6 presents the retention of ZVD in human vaginal epithelium after 24 h.

The degree of drug accumulation in studies using MB was relatively high and varied between 13.8 μg/cm² and 19.6 μg/cm² for MB1 and MB2, respectively. It is worth noting that the presence of gCS was found to improve the tissue retention of model microbicide agent as the amount of drug retained in the vaginal epithelium was significantly greater for microparticles MB1–MB2 as compared to control. A significantly higher ZVD tendency to tissue accumulation was observed in the studies using MB2, in which a faster rate of drug permeation was simultaneously observed. Therefore, it

**Figure 5.** Flux values (expressed as the amount of agent permeated per tissue area unit into the acceptor medium per unit time) of zidovudine from microparticles MB1 and MB2 and control (pure drug dispersed in HEC/SVF, pH 4.2) assessed at 2, 4, and 8 h of studies. *Significant differences with p < .05 in comparison to a pure drug in HEC/SVF (pH 4.2). Values are expressed as mean ± S.D. (n = 4).

**Table 3.** Quantitative analysis of zidovudine from microparticles MB1 and MB2 and control (pure zidovudine dispersed in HEC/SVF, pH 4.2) in acceptor medium, retained in human vaginal epithelium and on the tissue’s surface (drug recovery from donor compartment) after 24 h incubation (mean ± S.D.; n = 4).

| Compartment                | Parameter                                      | Control  | MB1            | MB2            |
|----------------------------|------------------------------------------------|----------|----------------|----------------|
|                            | After 8 h                                     | After 24 h| After 8 h      | After 24 h     |
| Acceptor medium            | Total amount of permeated drug per tissue’s area (μg/cm²) | 109.9 ± 14.9 | 150.6 ± 9.2 | 77.8 ± 17.5 | 112.3 ± 10.1 | 96.3 ± 20.3 | 133.3 ± 9.1 |
| Tissue's retentiona        | Total amount of drug per tissue’s area (μg/cm²)² | 6.7 ± 0.6 | 19.6 ± 1.5     | 13.1 ± 0.7     |
| Drug recovery from          | Percent of drug dose (%)                      | 94.0 ± 1.9 | 95.1 ± 2.2     | 91.2 ± 1.0     |
| donor compartmentb         |                                                 |          |                |                |

---

*aDispersion of microparticles-loaded ZVD (MB1–MB2) or ZVD in HEC/SVF (which amount corresponded to dose 5 mg) was placed on the tissue surface with an area of 0.81 cm²; concentrations of ZVD were determined in: bsolvent used for tissue extraction and cdrug dispersion aspirated from the surface of the tissue.
may be assumed that formulation MB2 potentially better comply with the requirements for microbicide drug delivery systems, and relatively high microbicidal retention in epithelium may assure protective activity against viral transmission.

3.4. In vitro anti-HSV 2 activity

Genital herpes is one of the most common ulcerative STDs, particularly in developing countries. Currently, anti-HSV treatment is based on symptomatic therapy with nucleoside analogs inhibiting viral replication (e.g. acyclovir). Despite acyclovir and its analogs are regarded as first-line drugs with a high safety profile, viral resistance is still an important limitation of effective treatment (Gupta et al., 2007; Sauerbrei et al., 2010).

Among STDs therapeutic strategies (including HSV infections), the development of topically (vaginally, rectally) applied microbicides is regarded as an attractive approach in preventing mucosal transmission of pathogens. From microbicide agent, it is expected that it will bind cell-free virus with high affinity and efficiently block its further spread to uninfected cells. Simultaneously, an ideal microbicide delivery system should provide intimate contact with the mucosal tissue and protect from infection by the residual active virus.

Despite chitosan and its derivatives are considered as polymers with antiviral potential capable of suppressing viral infections, the mechanism of its activity toward the HSV virus is poorly understood. In the present study, we hypothesized that chitosan impacts the direct contact of the herpes virus with mucosal cells. Thus, the goal was to assess the antiviral effect of gCS microparticles toward HSV-2 infection using viral attachment and penetration assay. The tests were performed in two keratinocyte cell lines commonly used to study microbicides in vitro (Michaelis et al., 2019; He et al., 2020). To test whether viral binding to the cell surface can be affected, HaCaT and VK2-E6/E7 cells were initially incubated at 4.0 ± 1 °C with HSV-2 in the presence of gCS microparticles, then the temperature was raised to 37.0 ± 1 °C to allow the virus to enter the cells. In the penetration assay, HSV-2 was initially allowed to attach to the cell surface at 4.0 ± 1 °C, then the unbound virus was removed, and gCS microparticles were applied at 37.0 ± 1 °C to test if formulations could block the virus from entering the cells. Based on the results from mucoadhesive and penetration studies, microparticles MB2 with polymer to drug mass ratio 5:1 and corresponding placebo formulation were chosen for in vitro anti-HSV tests at a concentration previously found nontoxic to the host cells (Szymanska et al., 2019).

The results presented in Figure 7(A) displayed the ability of gCS microparticles to affect HSV-2 attachment. However, profound differences in formulations’ activity toward HSV-2 between standard cell line HaCaT and vaginal epithelial cells were noted. Placebo formulation was found to be more effective in preventing viral attachment, especially regarding VK2-E6/E7 infected cells. Incubation with drug-free microparticles was responsible for approximately 80% inhibition of HSV-2 binding to the VK2-E6/E7 cell surface after 24 h post infection. In turn, MB2 was more effective in HaCaT cells, and the rate of reduction in HSV-2 titers was about 50%. It is
worth noting that placebo gCS microparticles blocked virus attachment in a similar manner as control acyclovir in vaginal epithelial cells. The observed alterations in the susceptibility of HSV-2 to tested formulations between cell lines might be related to different characteristics of the cell types. VK/E6E7 cells are vaginal epithelial cells, so they much better imitate \textit{in vitro} conditions observed in tests with the vaginal epithelium.

The results of the penetration assay displayed that HSV-2 was not significantly impaired ($p > .05$) for entry into HaCaT cells following exposure to both placebo or MB2 microparticles (Figure 7(B)). When tested in VK2-E6/E7 cells, both tested formulations inhibited viral entry comparably and showed less than 20% decrease in titers after 24 h incubation. These results of anti-HSV-2 inhibition are considerably lower than those received in the attachment assay.

Based on obtained data, it can be assumed that gCS itself exhibits anti-HSV-2 activity \textit{in vitro}. It is known that HSV entry and transmission require a combination of viral surface glycoproteins, including gD, gB, and gH–gL heterodimer (Chowdhury et al., 2012). With regard to the polycationic nature of chitosan and its ability to interact with glycosaminoglycans and glycoproteins present in the extracellular matrix, gCS may impair the function of these structural molecules engaged in HSV transmission. The plausible mode of gCS action involved in HSV-2 inactivation could be related to interaction with the virus surface through reactive amino moieties and the creation of a physical barrier that prevents viral interaction with the host cells receptors.

4. Conclusions

The obtained findings point to the feasible mucoadhesive and mucoretention behavior of gCS microparticles in contact with isolated human vaginal epithelium, which ability to adhere to mucosal tissue was comparable to those attained for the commercial mucoadhesive vaginal product. The ex \textit{vivo} studies on passive diffusion of drug through the vaginal tissue revealed that gCS increases the accumulation of model microbeicide in the vaginal epithelium but surprisingly does not facilitate its penetration across human vaginal tissue. It is worth noting that penetration and retention characteristics of model microbeicide may be modulated by alteration of the polymer–drug mass ratio in microparticles’ formulation. These results also demonstrated that gCS itself exhibits anti-HSV-2 activity \textit{in vitro}, and the mode of action is related to blocking viral attachment. Overall, presented findings indicate that gCS microparticles comply with the requirements for microbeicide drug carriers and hold promise in STDs prophylactic strategy as antiherpes adjunctive platforms. However, this assumption requires further \textit{in vivo} studies to assess the examined carriers’ efficacy and safety profile.

Acknowledgements

The authors are kindly grateful to Heppe GmbH, especially to Torsten Richter, the Head of QC/QA, for determining the molecular weight of chitosan glutamate. Special thanks also to Hetero Labs Limited (India) for providing ZVD sample and A.P. Instruments (Poland) for accomplishment particle size analysis.

Author contributions

Emilia Szymańska: conceptualization, methodology, formal analysis, investigation, writing – original draft, funding acquisition. Malgorzata Krzyżowska: methodology, investigation, writing – review and editing. Barbara Mikolaszek: methodology, writing – review and editing. Krzysztof Cäl: methodology, supervision. Jakub Tomaszweski: methodology. Sławomir Woźniński: supervision. Katarzyna Winnicka: writing – review and editing, supervision.

Disclosure statement

The authors declare that they have no competing financial interests or personal relationships which may influence the research studies presented in this paper.

Funding

This work is supported by the Medical University of Białystok (SUB/2/DN/20/001/2215) and Polish National Science Centre (NCN, 2017/01/X/NZ7/00973).

References

Ahmed TA, Aljaeid BM. (2016). Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther 10:483–507.
Ahsan SM, Thomas M, Reddy KK, et al. (2018). Chitosan as biomaterial in drug delivery and tissue engineering. Int J Biol Macromol 110:97–109.
Andersen T, Bleher S, Eide Flaten G, et al. (2015). Chitosan in mucoadhesive drug delivery: focus on local vaginal therapy. Mar Drugs 13:222–36.
AVAC. (2021). Global advocacy on HIV preventions. Microbicide candidates are in the early phases of development. Available at: https://www.avac.org/trial-summary-table/microbicides [last assessed 20 Jun 2021].
Bagdonaitė I, Nordén R, Joshi HJ, et al. (2015). A strategy for O-glycoproteomics of enveloped viruses-the O-glycoproteome of herpes simplex virus type 1. PLoS Pathog 11:e1004784.
Balasch-Risueño J, López M. (inventors). (2019). Gel comprising chlorhexidine. World Intellectual Property Organization WO2019/025599A1; PCT/EP2018/071155, 2019.02.07.
Benknap-Schnurch A, Hornof M. (2003). Intravaginal drug delivery systems. Design, challenges, and solutions. Am J Drug Deliv 1:241–54.
Caramella C, Ferrari F, Bonferroni MC, et al. (2010). Chitosan and its derivatives as drug penetration enhancers. J Drug Deliv Technol 20:5–13.
Chowdhury S, Naderi M, Chouljenko VN, et al. (2012). Amino acid differences in glycoproteins B (gB), C (gC), H (gH) and L (gL) are associated with enhanced herpes simplex virus type-1 (McKrae) entry via the paired immunoglobulin-like type-2 receptor σ. Virol J 9:112–20.
Clinical Trials. (2021). Clinical trials: safety and effectiveness of tenofovir gel in the prevention of human immunodeficiency virus (HIV-1) infection in women and the effects of tenofovir gel on the incidence of herpes simplex virus (HSV-2) infection. Available at: https://clinicaltrials.gov/ct2/show/NCT01386294 [last assessed 15 Jun 2021].
Cordis. (2021). Community Research and Development Information Service. Available at: https://cordis.europa.eu/result/rcn/57008_en.html [last assessed 15 Jun 2021].
Czechowska-Biskup R, Jarosińska D, Rokita B, et al. (2012). Determination degree of deacetylation of chitosan: comparison of methods. Prog Chem Appl Chitin Deriv 17:5–20.

Dott C, Tyagi C, Tomar LK, et al. (2013). Mucoadhesive electrospun nanofibrous matrix for rapid oral mucosal drug delivery. J Nanomater 2013:1–19.

Dunge A, Sharda N, Singh B, Singh S. (2005). Validated specific HPLC method for determination of zidovudine during stability studies. J Pharm Biomed Anal 37:1109–14.

European Medicines Agency. (2011). Draft guideline on quality and equivalence of topical products. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-equivalence-topical-products_en.pdf [last assessed 24 Jun 2021].

Frank LA, Chaves PS, Dott C, Tyagi C, Tomar LK, et al. (2013). Mucoadhesive electrospun nanofibrous matrix for rapid oral mucosal drug delivery. J Nanomater 2013:1–19.

Frank LA, Chaves PS, D’Amore CM, et al. (2017). The use of chitosan as cationic coating or gel vehicle for polymeric nanoparticles: increasing penetration and adhesion of imiquimod in vaginal tissue. Eur J Pharm Biopharm 114:202–12.

Frank LA, Sandri G, D’Autilia F, et al. (2014). Chitosan gel containing polymeric nanoparticles: a new formulation for vaginal drug delivery. Int J Nanomedicine 9:3151–61.

Frum Y, Khan GM, Sefcik J, et al. (2007). Towards a correlation between cationic coating or gel vehicle for polymeric nanocapsules: increasing penetration and adhesion of imiquimod in vaginal tissue. Eur J Pharm Biopharm 114:202–12.

Godin B, Touitou E. (2007). Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev 59:1152–61.

Godley MJ. (1985). Quantitation of vaginal discharge in healthy vol-
teers. Br J Obstet Gynaecol 92:739–42.

Gupta R, Warren T, Wald A. (2007). Genital herpes. Lancet 370:2127

He Y, Niu X, Wang B, et al. (2020). Evaluation of the inhibitory effects of acid/silver nanoparticle-based mucoadhesive hydrogel for improved microbicide mucoadhesion. Eur J Pharm Sci 144:335–40.

He Y, Niu X, Wang B, et al. (2020). Evaluation of the inhibitory effects of Lactobacillus gasseri and Lactobacillus crispatus on the adhesion of seven common lower genital tract infection-causing pathogens to vaginal epithelial cells. Front Med 7:284–92.

Karim SA, Karim QA. (2007). Diverse approaches useful for microbicide trials. Nature 449:24.

Loutfy SA, Elberry MH, Farroh KY, et al. (2020). Antiviral activity of chito-
san nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. Int J Nanomedicine 15: 2699–715.

McQuillan G, Krouson-Moran D, Flagg EW, Paulose-Ram R. (2018). Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief 304:1–8.

Meng J, Sturgis TF, Youan B-BC. (2011). Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci 44:57–67.

Merbahi M, Introini A, Fitzgerald W, et al. (2011). Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol 65:268–78.

Mesquita L, Galante J, Nunes R, et al. (2019). Pharmaceutical vehicles for vaginal and rectal administration of anti-HIV microbicide nanosys-
tems. Pharmaceutics 11:145–65.

Michaels M, Kleinschmidt MC, Bojkova D, et al. (2019). Omeprazole increases the efficacy of acyclovir against herpes simplex virus type 1 and 2. Front Microbiol 10:2790–7.

Namvar L, Olofsson S, Bergström T, Lindh M. (2005). Detection and typ-
ing of herpes simplex virus in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J Clin Microbiol 43:2058–64.

Orłowski P, Tomaszewska E, Gniadek M, et al. (2014). Tannic acid modi-fied silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection. PLoS One 9:e104113.

Owen DH, Katz DF. (1999). A vaginal fluid simulator. Contraception 59: 91–5.

Patel SK, Rohan LC. (2017). On-demand microbicide products: design matters. Drug Deliv Transl Res 7:775–95.

Potas J, Szymańska E, Basa A, et al. (2020). Tragacanth gum/chitosan polyelectrolyte complexes-based hydrogels enriched with xanthan gum as promising materials for buccal application. Materials 14: 86–101.

Russo E, Gaglianone N, Baldassari S, et al. (2014). Preparation, character-
ization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles. Colloids Surf B Biointerfaces 118:117–25.

Safarzadeh M, Sadeghi S, Azizi M, et al. (2021). Chitin and chitosan as tools to combat COVID-19: a triple approach. Int J Biol Macromol 183: 235–44.

Sandri G, Rossi S, Ferrari F, et al. (2004). Assessment of chitosan deriva-
tives as buccal and vaginal penetration enhancers. Eur J Pharm Sci 21:351–9.

Sauerbrei A, Deinhardt S, Zell R, Wutzler P. (2010). Phenotypic and geno-
typic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 86:246–52.

Sauerbrei A. (2016). Optimal management of genital herpes: current per-
spectives. Infect Drug Resist 9:129–41.

Seña AC, Bachman L, Johnston C, et al. (2020). Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis 20:181–91.

Shannon CL, Klausner JD. (2018). The growing epidemic of sexually transmitted infections in adolescents: a neglected population. Curr Opin Pediatr 30:137–43.

Sonaje K, Chuang E-Y, Lin KJ, et al. (2012). Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 9:1271–9.

Swarbrick J. (2007). Encyclopedia of pharmaceutical technology. 3rd ed. New York: Informa Healthcare.

Sweetman SC. (2011). Martindale: the complete drug reference. 37th ed. London: Pharma Press.

Szymanska E, Czarnomysy R, Jacyna J, et al. (2019). Could spray-dried microbeads with chitosan glutamate be considered as promising vagi-

nal microbicide carriers? The effect of process variables on the in vitro functional and physicochemical characteristics. Int J Pharm 568: 118538.

Szymanska E, Orłowski P, Winnicka K, et al. (2018). Multifunctional tannic acid/silver nanoparticle-based mucoadhesive hydrogel for improved local treatment of HSV infection: in vitro and in vivo studies. Int J Mol Sci 19:387.

Szymanska E, Winnicka K, Wieczorek P, et al. (2014). Influence of unmodified and β-glycerophosphate cross-linked chitosan on anti-Candida activity of clotrimazole in semi-solid delivery systems. Int J Mol Sci 15:17765–80.

Tien D, Schnaare RL, Kang F, et al. (2005). In vitro and in vivo character-
ation of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21:845–53.

World Health Organization. (2021). Global health sector strategy on sexu-
tally transmitted infections 2016–2021. Available at: www.who.int/ reproductivematters [last assessed 20 Jun 2021].

Zhang Y, Chan HF, Leong KW. (2013). Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev 65: 104–20.